AlphaMaven AlphaMaven

Sofinnova Partners grows crossover fund by 63% to €725m, eyes European life sciences funding gap

Reported by AltAssets ·HedgeCo.Net
Nov 16, 2026· 2 min read
Save Post LinkedIn Email
Key Takeaways
  • • Sofinnova Partners announced the final close of Sofinnova Crossover II at €725 million ($815 million) on November 16, 2026, above its original target.
  • • The fund will back about 15 high-growth companies, with roughly 80% of capital invested in Europe, according to partner Kinam Hong speaking to Fierce Biotech.
  • • Focus areas include immunology and inflammation, oncology, central nervous system disorders, rare disease and cardiometabolic disease, targeting clinical-stage biopharma and medtech.
  • • Early holdings include Ireland's Neurent Medical, Denmark's Hemab Therapeutics and the UK's CellCentric; Sofinnova's total assets across strategies now exceed €5 billion.
  • • The predecessor Crossover I backed LimFlow (acquired by Inari Medical for $415 million in 2023) and Calliditas Therapeutics (acquired by Asahi Kasei for more than $1 billion in 2024).
Summary
Sofinnova Partners, the Paris-, London- and Milan-based life sciences venture firm, announced on November 16 the final close of Sofinnova Crossover II at €725 million ($815 million), exceeding its original fundraising target. The fund plans to back about 15 high-growth companies, focused primarily on European clinical-stage biopharma and medtech businesses that require capital to reach commercialization, with selective investments in the United States and other markets.

According to partner Kinam Hong, who spoke to Fierce Biotech, about 80% of the fund will be deployed in Europe. Target therapeutic areas include immunology and inflammation, oncology, central nervous system disorders, rare disease and cardiometabolic disease. Crossover II has already begun investing, with initial holdings in Ireland's Neurent Medical, Denmark's Hemab Therapeutics and the UK's CellCentric. Per Fierce, the close brings Sofinnova's assets across all strategies to more than €5 billion.

Chairman and Managing Partner Antoine Papiernik said the fund's size reflects the maturing European life sciences ecosystem and growing demand for capital that can carry companies into global markets. The predecessor, Crossover I, backed companies that were subsequently acquired or went public, including LimFlow, which Inari Medical bought for $415 million in 2023, and Calliditas Therapeutics, which Asahi Kasei acquired for more than $1 billion in 2024.

For allocators, crossover strategies sit between venture capital and public equity and depend on a functioning exit window. An above-target close for a Europe-focused vehicle suggests limited partners view late-stage biotech financing gaps on the continent as an opportunity rather than a warning sign.

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

2 outlets

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

AltAssets Sofinnova Partners grows crossover fund by 63% to €725m, eyes European life sciences funding gap HedgeCo.Net Sofinnova Partners Closed Its Crossover II Fund at €725 Million, Above Target, to Back Late-Stage European Life Sciences Companies: